Tag: Juliet Moritz

Patient and Stakeholder Engagement

Working with Advocates: Understanding Patient Concerns and Why They Matter in Clinical Trials

Patient advocacy groups have exploded in number and scope in recent years and in many ways are reshaping the drug development landscape, from trial design to recruitment support to participation in the regulatory approval process. Thousands of organizations now advocate for millions of patients, and while many patients and families eagerly engage with these groups,...

Patient and Stakeholder Engagement

Patient Engagement Expert to Address Orphan Drug Congress April 11

DURHAM, N.C., March 25, 2019 — Premier Research’s head of patient engagement will discuss a patient-centered look at drug development at the World Orphan Drug Congress (WODC) USA in Oxon Hill, Maryland. Juliet Moritz, Premier Research’s newly appointed vice president of patient and stakeholder engagement (PASE), will present From the End to the Beginning: A Patient-Centric...

Patient and Stakeholder Engagement

Premier Voices #8: Engaging Patients in Clinical Trials w/ Alan Thomas & Juliet Moritz

Clinical research certainly has evolved over the past three decades. There are more trials crossing a broader spectrum of indications, and advances in study design and execution have dramatically changed the way drugs and medical devices are evaluated and sold. But perhaps no change has been more significant than the growth in engagement on the...

Patient and Stakeholder Engagement

Patient Engagement Lead to Address iCAN Summit July 12

DURHAM, N.C., July 2, 2018 — Premier Research’s head of patient engagement will talk about the role of natural history studies in clinical research at the International Children’s Advisory Network’s Research & Advocacy Summit on July 12 in Edinburgh, U.K. Juliet Moritz, the CRO’s Executive Director, Program Strategy, Rare Disease and Pediatrics/Patient Engagement, will discuss...

Patient and Stakeholder Engagement

Patient Engagement Expert to Speak on Rare Patient Advocacy

DURHAM, N.C., OCTOBER 20, 2017 — Premier Research’s head of patient engagement will address patients’ emerging role in the development of novel drugs October 23 at the Cambridge Rare Disease Network Summit in Cambridge, U.K. Juliet Moritz, the CRO’s Executive Director for Patient Engagement and Strategic Development, will discuss how patient advocacy groups are greatly...

Clinical Research: Phase 1 - Phase 4

Registry and Natural History Studies: Vital, Contrasting Roles in Clinical Research

Both registry studies and natural history studies play important roles in rare disease research. Understanding the differences between the two types of studies and how they can be used to inform clinical development can help sponsors plan for success.

Patient and Stakeholder Engagement

Gaining Strength: Webinar to Explore Advocates’ Role in Drug Development

DURHAM, N.C., August 10, 2016 — Patient advocacy groups play an important and growing role in developing drugs to treat cancer and rare diseases, contributing to study design, recruiting patients, and even directly funding clinical trials. At a September webinar, Premier Research will team with rare disease advocacy organization Global Genes to explore this important...

Premier Research Bolsters Rare Disease and Oncology Drug Development Expertise with New Hires

DURHAM, N.C., June 13, 2016 — Premier Research is expanding its international organization of experts in rare disease amid continued growth in the field — especially in rare oncology, which has surpassed one-third of the company’s rare disease work. “Development of novel compounds for treatment of unmet medical needs historically has been overlooked by big pharma,...

Medical and Regulatory Affairs

What’s Ahead in Orphan Drugs? Attend Our June 1 Webinar

DURHAM, N.C., May 31, 2016 — Treatment of rare indications is turning a promising corner as regulators and lawmakers boost incentives and guidance in these areas of unmet medical need. Three experts from Premier Research will look at financial aid, expedited reviews, and other avenues available to orphan drug developers in a webinar on Wednesday, June...

March 29 Webinar Offers a Revealing Look at Rare Cancer Research

DURHAM, N.C., March 29, 2016 — Recruiting hard-to-find patients and making the most of small data samples are familiar challenges in study of rare cancers, and there’s so much more. How much risk is too much? What about adaptive design and other approaches to easing the burden on patients and shortening development timelines? Sachin Kulkarni...